Heptanoin, Tri-
GLUT1 Deficiency Syndrome
University of Texas Southwestern Medical CenterSmall moleculePhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the GLUT1 Deficiency Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sodium Lactate Radboud University Medical Center | Early Phase 1 | CC |
Same molecule, other indications
Heptanoin, Tri- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →